# Synthetic Egg:Sperm Fusion Assay (SEFA): A Diagnostic Test for Male Fertility

> **NIH NIH R43** · PS-FERTILITY, INC. · 2024 · $195,000

## Abstract

Abstract: SNYTHETIC EGG:SPERM FUSION ASSAY: A DIAGNOSTIC TEST FOR MALE FERTILITY
 The establishment of PS-Fertility, C-Corp was motivated by: 1) our recent findings from the laboratory that
phosphatidylserine (PS) on the surface of viable sperm is necessary for sperm:egg fusion; 2) that sperm can
fuse with myoblast cells in a PS-dependent manner; and 3) the inability of conventional semen analysis assays
to provide meaningful information about sperm function. Our overall goal of this SBIR is to refine our simple rapid
synthetic egg:sperm fusion assay and further develop our business model. The fusion assay will serve as a
surrogate assay for sperm:egg fusion, to quantify the fusogenic fertilization-competent sperm in an ejaculate.
 Clinicians view semen analysis as a perfunctory assay, rather than an insightful test to acquire information
toward improved assisted reproductive technique strategies. Our market research, performed as part of the NSF
I-Corps program, revealed that, overwhelmingly, clinicians would welcome a diagnostic tool that could provide
new information about male infertility, specifically sperm health/function.
 The premise for this application stems our preliminary studies, where we find an unexpected exposure of the
lipid phosphatidylserine (PS), which is normally associated with apoptotic cells, on the surface of viable and
motile sperm. Further, PS recognition receptors are expressed on the oocytes, and blocking/loss of some of
these receptors impairs fertilization.
 In this Phase 1 SBIR application, we will further develop our synthetic egg:sperm fusion assay (SEFA) that
will test the fusion (fertilization) competency of sperm cells. To our knowledge, there are no semen analysis tests
that provide information about the potential ability of a sperm to fertilize an egg. In Aim 1 we will demonstrate
the feasibility of better quantifying male infertility though a new fertility kit and in Aim 2 we will perform a
pilot study to evaluate the use of the new kit with a larger cohort of real-world samples.
 Development of this male fertility test `SEFA' will provide fertility experts and thus patients with information
about male fertility that is currently not available from any other diagnostic. This information will aid in
personalizing fertility treatments and reducing emotional and economic costs.

## Key facts

- **NIH application ID:** 10821689
- **Project number:** 1R43HD114303-01
- **Recipient organization:** PS-FERTILITY, INC.
- **Principal Investigator:** JEFFREY J LYSIAK
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $195,000
- **Award type:** 1
- **Project period:** 2024-02-09 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10821689

## Citation

> US National Institutes of Health, RePORTER application 10821689, Synthetic Egg:Sperm Fusion Assay (SEFA): A Diagnostic Test for Male Fertility (1R43HD114303-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10821689. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*